Semaglutide in Nonalcoholic Fatty Liver Disease

NCT05813249 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

180

Enrollment

OTHER_GOV

Sponsor class

Conditions

Non-alcoholic Fatty Liver Disease

Interventions

DRUG: Rybelsus Oral Product
DRUG: Ozempic Injectable Product
DRUG: Tocopherol and/or Actos

Sponsor

Zagazig University